FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Yahoo Finance

Moleculin Issues New Positive AML Overall Survival Data:

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...
ascopubs.org

Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape

The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
The American Journal of Managed Care

Studies Examine Real-World Pediatric AML Treatment and Outcomes

Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Stocktwits on MSN

SLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomes

Stergiou said the delayed timeline for reaching the final event trigger has increased optimism for the Regal trial. ・The CEO also disclosed that some Regal patients remain on treatment more than three ...